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ABSTRACT 
Central serous chorioretinopathy is a common acquired maculopathy. Multiple studies showed that 
photodynamic therapy is useful treatment for acute and chronic central serous chorioretinopathy. The 
exact mechanism of photodynamic therapy in treating central serous chorioretinopathy is not clear, but it is 
thought to be caused by short-term choriocapillaris hypoperfusion and long-term choroidal vascular 
remodeling, leading to a reduction in choroidal congestion, vascular hyperpermeability and extravascular 
leakage. Furthermore, photodynamic therapy seems to be an effective means of improving or stabilizing 
visual acuity in patients with central serous chorioretinopathy. 
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INTRODUCTION  
Central serous chorioretinopathy (CSC) is characterized by a 
serous detachment of the neurosensory retina in the macular 
region, occasionally associated with detachment of the retinal 
pigment epithelium (RPE).  The most surprising aspect of the 
disease is the relative preservation of retinal function 
regardless prolonged separation from the RPE. Males are 
mostly affected to have this condition and the average age is 
between 20 and 50 years. The usual presenting symptoms are 
significant loss of visual acuity and development of permanent 
visual loss. Visual impairment is secondary to persistent serous 
detachments of the neurosensory retina leading to cystoid 
edema of the retina and diffuses decompensation of the RPE 
[1]. The photoreceptors might have a critical role in this 
process, because they are separated from their source of 
nutrients when the retina is detached [2]. Some patients, 
particularly older adults, can develop choroidal 
neovascularization, which leads to severe visual loss [3]. 
The pathogenesis of CSC is still not completely understood. 
However, it is well known that the subneural retinal fluid 
originates from the choroid. At first it was believed that fluid 
from the choroid drain away into subretinal space through 
defects in tight junctions between the RPE cells due to 
breakdown of the blood-retinal barrier. However, this theory 
does not explain the beneficial effect of laser photocoagulation 
which consequences in permanent RPE barrier breakdown. 
Another theory suggested that lost of normal RPE cells polarity 
acts as a trigger for fluid pumping from the choroid to the 
retina, causing a neurosensory detachment [4]. This theory was 
failed after increased using of indocyanine green angiography 
(ICGA) which reveals multifocal areas of choroidal vascular 
hyperpermeability in CSC, which leads to mechanical disruption 
of RPE barrier with subsequent accumulation of subretinal fluid, 
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supporting the theory that the underlying pathophysiology is at 
the choroidal level [5,6]. No new vessels are usually present in 
CSC, but the defect seems to affect choroidal vessels. Any 
therapy that decreases the excess of choroidal permeability 
may be potentially helpful in CSC cases [7]. 
Therefore recent studies examining the pathogenesis of CSC 
support the hypothesis that RPE decompensation may be a 
result of underlying choroidal vasculature hyperpermeability [8-
11]. Some authors reported that choroidal vascular 
hyperpermeability was seen in most symptomatic eyes with 
CSC [4,6]. Prunte et al. showed delayed choroidal capillary 
lobular filling in areas of hyperpermeability and proposed that 
localized capillary and venous congestion in the affected 
lobules impaired the circulation, produced ischemia, and 
allowed increased choroidal exudation and a focally 
hyperpermeable choroid [12]. Increased choroidal permeability 
along with local high perfusion and increased hydrostatic 
pressure allows profusion choroidal fluid to accumulate and 
produces a RPE detachment. As the detachment grows, the 
target junctions between RPE cells are broken, and a focal 
defect of the blood-retinal barrier develops, later resulting in 
neural retinal detachment [13-14]. Some investigators revealed 
that subfoveal choroid in the eyes with CSC, even in the fellow 
eyes are thicker than that in normal eyes because of choroidal 
vascular hyperpermeability [9,15]. They used optical coherence 
tomography (OCT) to evaluate choroidal hyperpermeability by 
measuring choroidal thickness. Interestingly, recent studies 
reveal that corticosteroids can influence the production of the 
nitric oxide, prostaglandins and free radicals within the 
choroidal circulation. All three substances participate in the 
autoregulation of blood flow within the choroid [16].  
The treatment of central serous chorioretinopathy has not 
been well-established. Different therapeutic approaches have 
been tried to manage this condition, including beta-blockers, 
acetazolamide, vitamins and non-steroidal anti-inflammatory 
drugs, but none of these had explicit benefits [17]. In past 
decades, argon laser photocoagulation of extrafoveal leakage 
points was the standard of CSC treatment [18,19]. It is the only 
therapy proved beneficial by large clinical trials. Laser 
treatment induces a local inflammatory reaction on RPE, thus 
decreasing RPE leakage while choroidal hyperpermeability 
remain unchanged [20]. The evidence of long follow-up studies 
shows a reduction of serous detachment with lack of 
improvement in final visual acuity or a reduction in the 
incidence of recurrences [21-23]. Laser photocoagulation 
cannot be performed in the foveal avascular zone. Laser 
therapy may result adverse effects such as secondary choroidal 
neovascularization or central scotomas [24-26]. 
Another treatment option is photodynamic therapy (PDT). PDT 
originally was intended to cause regression of choroidal 
neovascularization (CNV) secondary to age related macular 
degeneration and recently is used for neovascular age-related 
macular degeneration, pathologic myopia and ocular 
histoplasmosis caused CNV treatment. The exact mechanism of 
PDT on CSC is not well-known. It has been suggested that PDT 
may induce choriocapillaris damage and vascular remodeling 
thus decreasing choroidal hyperpermeability [12,27-32]. 
Maruko et al. using enhanced depth imaging OCT, reported 
reduced choroidal thickness 1 month after PDT treatment in 
chronic CSC patients [20]. These findings are compatible with 
ICGA showing a transitory hypoperfusion [11]. Another authors 
hypothesized that PDT acts by both decreasing choroidal 
hyperpermeability and tightening the blood retinal barrier at 
the level of the RPE resulting in resolution of subretinal fluid 
[1]. 
Patients with chronic forms of CSC may benefit from a 
decreased choroidal vascular permeability. Some authors 
suggest that verteporfin may show a high affinity for RPE [1,33]. 
Verteporfin is a benzoporphyrin derivate which is used as a 
photo sensitizer for PDT to eliminate the abnormal blood 
vessels in the eye. It is known that the primary effect of PDT 
seems to be damage of the choriocapillaris endothelium, 
swelling, fragmentation, detachment from its basement 
membrane and degeneration [31]. Another possible 
explanation for the positive effects of this therapy concerns the 
inflammatory reaction precipitated by PDT. Verteporfin may be 
deposited within the serous fluid under the macula and its 
activation may release free radicals and pro-inflammatory 
factors that induce a permanent adhesion between the 
neurosensory retina and RPE. This mechanism may explain the 
occurrence of inflammatory changes in the RPE [7].   Otherwise 
the vascular endothelial damage known to be the major 
hallmark of photodynamic tissue effects is induced by direct 
interaction of singlet oxygen with the lipids of the endothelial 
cytoplasmic membranes. Recanalization of the choriocapillaris 
begins to occur within a short interval after doses of therapy. 
Maintenance of structural integrity histologically of the 
overlying photoreceptors seems to be the result of limited 
hypoxia or thermally enhanced phototoxic damage [31]. 
Histologic studies on animal models and humans have shown 
that PDT induces the regression of subretinal newly formed 
vessesls as well as obliteration of the vessels of the inner 
choriocapillaris [32].  
 The standard regime for using PDT is to give patient 
intravenous verteporfin at a dose of 6 mg/m2 over 10 minutes. 
Then, 5 minutes later, diode laser at a wavelength of 600-689 
nm and energy of 50 mJ/cm2 over 83 seconds is directed to the 
target lesion of the eye. Possible ocular side effects include RPE 
atrophy and rips, secondary choroidal neovascularization, and 
ischemia of choriocapillaris. To minimize adverse events, 
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research has targeted half-dose half fluence and minimal-
fluence PDT [35]. Half-dose or low-fluence PDT with verteporfin 
is effective in inducing reabsorption of subretinal or intraretinal 
fluid with some beneficial visual outcomes in the majority of 
patients with CSC [33,45]. 
 
PDT is not completely harmless to ocular structures [20,30-
32,36-40]. Choriocapillaris thrombosis and choroidal perfusion 
and permeability changes have been demonstrated. These 
reports show no early neural retina or RPE changes with 
standard verteporfin doses [30,31]. Some studies showed that 
standard dose PDT might be associated with choriocapillaris 
hypoperfusion that may result in decreased vision [41]. In 
recent years, several different studies have supported the good 
results of PDT with standard doses of verteporfin to treat 
chronic CSC [7,33,35-47]. However, these studies were 
performed with a small number of patients and short follow-up. 
In order to avoid PDT related complications half-dose or low-
fluence PDT has been suggested by different authors. Higher 
selectivity of the choriocapillaris was achieved with a lower 
fluence PDT, while higher fluence emission resulted in closure 
of the deeper choroidal vessels and focal alterations in the RPE. 
PDT has shown better results on visual acuity and anatomical 
outcome compared with photocoagulation in chronic forms of 
CSC, with fewer complications [1,7,45-47,49-53]. Changes in the 
average neural retina thickness of eyes treated by PDT could be 
supported by the long-standing effects of vascular remodeling 
in the underlying choroid [20,30]. Photodynamic therapy with 
verteporfin might induce temporary choriocapillaris occlusion 
and endothelial changes, this might reduce the vascular 
permeability and decrease fluid passage toward the retina 
[45,49]. Moreover, RPE cells damaged by light-activated 
verteporfin might be replaced by new ones possible recovery 
from the metabolic impairment at the RPE level [34,49]. 
 
HYPOTHESIS  
Clinical  and experimental evidence indicates that besides 
closing the neovascular membrane this treatment also 
produces ischemia of the underlying choriocapillaris, induced 
by direct action on the choriocapillaris endothelium with 
choriocapillaris occlusion and resulting in hypoperfusion of the 
choriocapillaris in the short term and remodeling of choroidal 
vascular over time. This effect of PDT on the choroid could be 
used to reduce choroidal congestion and vascular 
hyperpermeability, which is an important factor in CSC 
pathogenesis.  
 
 
CONCLUSION 
PDT seems to be an effective therapy of improving or stabilizing 
visual acuity in patients with central serous chorioretinopathy. 
However, more studies are needed to manifest the benefits, 
efficacy and long-term safety of PDT in the treatment of CSC.. 
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